

Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture


AD Lauritzen, MC von Euler-Chelpin, E Lynge, I Vejborg, M Nielsen, N Karssemeijer, M Lillholm



Study design

Image data and screening information of examinations performed from January 2004 to December 2019 as part of BreastScreen Norway were used in this retrospective study. Prior screening examinations from women who were later diagnosed with cancer were assigned an AI risk score by a commercially available AI system (scores of 1–7, low risk of malignancy; 8–9, intermediate risk; and 10, high risk of malignancy). Mammographic features of the cancers based on the AI score were also assessed. The association between AI score and mammographic features was tested with a bivariate test.

Results



Conclusion

More than one in three cases of screen-detected and interval cancers had the highest AI risk score at prior screening, suggesting that the use of AI in mammography screening may lead to earlier detection of breast cancers.

SPM-SMR-001-XXX X.X

© 2023 ScreenPoint Medical BV. Transpara® is a registered trademark of ScreenPoint Medical BV. Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of ScreenPoint Medical. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because ScreenPoint Medical materials are distributed through websites, eBroadcasts and tradeshow, it is not always possible to control where such materials appear. For specific information on what products and features are available in a particular country, please contact your local representative or write to info@screenpointmed.com

Toernooiveld 300, 6525 EC, Nijmegen, The Netherlands // Tel.: +31 24 202 00 20 // info@screenpointmed.com